Search
Urogen Pharma Ltd
URGNAdd to Watchlist
37.940USD
+1.140+3.10%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.85BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.10%
5 Days
+7.11%
1 Month
+40.36%
6 Months
+62.00%
Year to Date
+62.00%
1 Year
+191.40%
Key Figures
37.110Open
39.585High
1.13MVolume
LossP/E TTM
27.80P/E Dynamic
--Dividend TTM
2.34%Turnover Ratio
36.800Prev. Close
37.110Low
34.46MTurnover
LossP/E Static
-17.39P/B
0.00%Div Yield TTM
-53.15%ROA
32.37052wk High
1.57Volume Ratio
-126.87MNet Profit
48.35MShares
-2.7353EPS TTM
1.61Beta
--ROE
3.60552wk Low
6.73%Amplitude
91.88%Gross Margin
1.85BMarket Cap
9.15Reward/Risk
4.22%Risk Rate
TradingKey Stock Score of Urogen Pharma Ltd
Currency: USD Updated: 2026-07-01Key Insights
Urogen Pharma Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.12.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Urogen Pharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Urogen Pharma Ltd Highlights
StrengthsRisks
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.73% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 109.79M.
Undervalued
The company’s latest PE is -13.87, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.29M shares, decreasing 25.32% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 6.68K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
37.125
Target Price
+0.88%
Upside Space
Urogen Pharma Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Urogen Pharma Ltd Info
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Ticker SymbolURGN
CompanyUrogen Pharma Ltd
CEOBarrett (Elizabeth A)
Websitehttps://www.urogen.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Urogen Pharma Ltd (URGN)?
The current price of Urogen Pharma Ltd (URGN) is 37.94.
What is the symbol of Urogen Pharma Ltd?
The ticker symbol of Urogen Pharma Ltd is URGN.
What is the 52-week high of Urogen Pharma Ltd?
The 52-week high of Urogen Pharma Ltd is 32.37.
What is the 52-week low of Urogen Pharma Ltd?
The 52-week low of Urogen Pharma Ltd is 3.60.
What is the market capitalization of Urogen Pharma Ltd?
The market capitalization of Urogen Pharma Ltd is 1.83B.
Is Urogen Pharma Ltd (URGN) currently rated as Buy, Hold, or Sell?
According to analysts, Urogen Pharma Ltd (URGN) has an overall rating of Buy, with a price target of 37.12.
What is the Earnings Per Share (EPS TTM) of Urogen Pharma Ltd (URGN)?
The Earnings Per Share (EPS TTM) of Urogen Pharma Ltd (URGN) is -3.19.